| Literature DB >> 9651152 |
R J Cregge1, S L Durham, R A Farr, S L Gallion, C M Hare, R V Hoffman, M J Janusz, H O Kim, J R Koehl, S Mehdi, W A Metz, N P Peet, J T Pelton, H A Schreuder, S Sunder, C Tardif.
Abstract
A series of P2-modified, orally active peptidic inhibitors of human neutrophil elastase (HNE) are reported. These pentafluoroethyl ketone-based inhibitors were designed using pentafluoroethyl ketone 1 as a model. Rational structural modifications were made at the P3, P2, and activating group (AG) portions of 1 based on structure-activity relationships (SAR) developed from in vitro (measured Ki) data and information provided by modeling studies that docked inhibitor 1 into the active site of HNE. The modeling-based design was corroborated with X-ray crystallographic analysis of the complex between 1 and porcine pancreatic elastase (PPE) and subsequently the complex between 1 and HNE.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9651152 DOI: 10.1021/jm970812e
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446